Table 1.
[18F]FLT clinical studies: correlation with Ki-67
| Reference | Cancer | Results |
|---|---|---|
| Vesselle et al. 44 | NSCLC (n = 11) | SUV: r = 0.84; KI: r = 0.92 |
| Buck et al. 45 | Pulmonary nodules (n = 15)1 | SUV: r = 0.92 |
| Muzi ett al. 46 | NSCLC (n = 17) | KI: r = 0.92 |
| Choi et al. 47 | Glioma (n = 9) | SUV: r = 0.817 |
| Kenny et al. 40 | Breast cancer (n = 12) | SUV: r = 0.79; KI: r = 0.92 |
| Ullrich et al. 48 | Glioma (n = 11) | SUV: NC2; KI: r = 0.883 |
| Hatakeyama et al. 8 | Glioma (n = 18) | SUV: r = 0.89 |
| Francis et al 51 | Colorectal cancer (n = 10) | SUV: r = 0.8 |
| [18F]FLT: clinical studies monitoring response to therapy | ||
| Pio et al. 54 | Breast cancer | Early changes in [18F]FLT correlated with later changes of the tumor marker, CA27.29 |
| Herrmann et al. 57 | Non-Hodgkin’s Lymphoma | Early reductions in [18F]FLT SUV detected positive response to R-CHOP/CHOP |
| Chen et al. 56 | Glioma | Can identify responders versus nonresponders after 1 – 2 weeks in patients treated with bevacizumab and irinotecan |
| Kenny et al. 40, 53 | Breast cancer | Patients responding to FEC4 chemotherapy exhibited a 53% reduction in [18F]FLT KI value |
| Sohn et al. 55 | Adenocarcinoma of the lung | Patients responding to Gefitnib treatment displayed a 36% reduction in [18F]FLT SUV |
1
Excluded 4 benign lesions from analysis;
2
no correlation;
3
compartmental modeling showed a correlation of r = 0.88 for k3 versus Ki-67 expression;
4
5-fluorouracil/epirubicin/cyclophosphamide